851-P: Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2D and CVD or CV Risk in the U.S.

Abstract

There is limited US real-world evidence on changes in use of antihyperglycemic agents (AHA) by age in patients with T2D and CVD or CV risk. Patients with T2D and CVD or T2D and an additional CV risk factor were identified from 2015-2019 in the MarketScan data. Patients with continuous enrollment for the calendar year of the index date (first observed CVD diagnosis [Dx]/CV risk factor) and no CVD Dx before or in the same year as the index date (CV risk cohort only) were included. Patients were followed for each year they were continuously enrolled or until a CVD Dx (CV risk cohort). AHA classes received in each year were reported by cohort and age group ( Disclosure R. Mody: Employee; Self; Eli Lilly and Company. J. Meyers: None. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. J. A. Levine: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. K. Davis: Research Support; Self; AstraZeneca, Eisai Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi, Vertex Pharmaceuticals Incorporated.